The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Try the newly designed Company Pages!
Switch now

Keryx Biopharmaceuticals

  • KERX
  • NASDAQ
  • Consumer Products
  • Latest 14.68
  • Currency US$
  • Change 0.47
  • Percent Change 3.308 %
  • Volume 1,627,553
  • Wed Jul 23, 2014 04:00 PM EDT NASDAQ data delayed 15 minutes.
  • Open 14.27
  • Previous Close 14.21
  • High 14.68
  • Low 14.13
  • Bidx0 0.0000
  • Askx0 0.0000
  • 52-week High03/31 17.46
  • 52-week Low08/19 8.29
  • Beta 4.25
  • Market Cap 1,334.56M
  • EPS -0.70
  • P/E
  • Forward P/E 77.26
  • PEG
  • Annual Dividend 0.0000
  • Yield

News

Financials & Calendars

Income Statement

  • Sales $10,000,000
  • Earnings $-58,210,000
  • Return on Equity n/a

Cash Flow

  • Cash Flow --
  • Cash $105,250,000
  • Current Ratio 9.56

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in U.S. dollars.

Balance Sheet

  • Assets $160,320,000
  • Liabilities $16,410,000
  • Liabilities-to-Equity Ratio 0.11

Price Ratios

  • Price to Sales 133.46
  • Price to Book 9.27
  • Price to Cash Flow n/a

Event Calendar

Event Last   Next  
Earnings May 8 $-0.10 Jul 30 $-0.23
Surprises May 8 30.00% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 24, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.

Related Securities
Symbol Type Latest % Chg

Officers

  • Michael P. Tarnok Chairman of the Board of Direc
  • Ron Bentsur Chief Executive Officer and Di
  • Company Type: n/a
  • Company Status: n/a
  • Full-time Employees: n/a
  • Incorporation: United States,
    n/a
  • Top 1000 Ranking: Profit: n/a
    Revenue: n/a
    Assets: n/a

Head Office

750 LEXINGTON AVENUE
NEW YORK, NY

Phone: (212)-531-5965
Fax: (212)-5315961

ir@keryx.com
www.keryx.com

Ideas & Discussion

Live Discussion of KERX on StockTwits